Importantly, more than 40% NSCLC with gCHEK2m harbored actionable drivers with proven therapeutics treatments that could potentially extend to 51% if considering other KRAS G12 isotype mutations. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.